Cumberland Pharmaceuticals Inc.
CPIX
$3.40
$0.144.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.97% | 8.06% | -2.60% | -8.55% | -9.09% |
| Total Other Revenue | -34.76% | -34.76% | -34.76% | 53.33% | 53.33% |
| Total Revenue | 11.34% | 5.81% | -4.26% | -6.45% | -7.05% |
| Cost of Revenue | 2.35% | 0.69% | 8.56% | -14.58% | -13.91% |
| Gross Profit | 13.24% | 6.82% | -6.58% | -4.64% | -5.46% |
| SG&A Expenses | -1.38% | -1.83% | -3.28% | 3.62% | 6.79% |
| Depreciation & Amortization | -0.69% | 0.08% | -0.22% | 11.50% | 5.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.70% | -2.25% | -3.20% | -1.70% | 1.47% |
| Operating Income | 60.62% | 50.05% | -3.57% | -31.36% | -86.44% |
| Income Before Tax | 71.31% | 60.25% | -2.88% | -345.72% | -479.65% |
| Income Tax Expenses | -162.52% | -156.77% | -149.89% | -14.08% | -20.61% |
| Earnings from Continuing Operations | 71.79% | 60.82% | -1.78% | -335.79% | -461.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.32% | 234.96% | -170.23% | -141.88% | -108.35% |
| Net Income | 71.75% | 61.08% | -3.19% | -348.15% | -481.30% |
| EBIT | 60.62% | 50.05% | -3.57% | -31.36% | -86.44% |
| EBITDA | 159.61% | 188.06% | -20.00% | -93.63% | -746.49% |
| EPS Basic | 71.13% | 59.86% | -3.90% | -355.21% | -492.48% |
| Normalized Basic EPS | 55.30% | 32.38% | -112.21% | -194.40% | -344.70% |
| EPS Diluted | 70.19% | 58.21% | -4.79% | -343.99% | -463.46% |
| Normalized Diluted EPS | 54.96% | 32.03% | -111.31% | -192.89% | -341.06% |
| Average Basic Shares Outstanding | 2.24% | 0.27% | -1.67% | -1.74% | -1.69% |
| Average Diluted Shares Outstanding | 2.80% | 0.54% | -2.33% | -2.40% | -2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |